Literature DB >> 21243937

Allergy workup in immediate-type local reactions to glatiramer acetate.

J Sánchez-López1, P Rodríguez del Rio, B Cases-Ortega, C Martínez-Cócera, M Fernández-Rivas.   

Abstract

Local reactions to glatiramer acetate are common, but few cases of hypersensitivity reaction have been reported. We present 3 patients with multiple sclerosis who suffered immediate-type local reactions after subcutaneous injection of glatiramer acetate. Skin prick test (SPT), intradermal test (IDT), and determination of immunoglobulin (Ig) E to glatiramer acetate were performed in patients and controls (enzyme-linked immunosorbent assay). The results of SPT were all negative. Those of IDT in controls were negative at concentrations below 200 microg/mL, but positive for patients 1, 2, and 3 at 2, 20, and 200 microg/mL, respectively. Serum IgE to glatiramer acetate in patient 1 was 2.1 times higher than in the controls, whereas no differences were found between controls and patients 2 and 3. Glatiramer acetate was safely reintroduced in patients 2 and 3. The results obtained for patient 1 suggest that an IgE-mediated mechanism was probably involved. In conclusion, IDT and serum IgE determination to glatiramer acetate seem useful for identifying allergic reactions among the common local reactions induced by this drug.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21243937

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  2 in total

Review 1.  Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols.

Authors:  Guadalupe Marco-Martín; Pilar Tornero; Alicia Prieto; Alejandro La Rotta; Teresa Herrero; Maria Luisa Baeza
Journal:  Neurol Clin Pract       Date:  2020-04

2.  Flare up reaction during provocation test to glatiramer acetate in a patient with allergy to interferon beta1a.

Authors:  Paola L Minciullo; Gioacchino Calapai; Sebastiano Gangemi
Journal:  Allergy Asthma Immunol Res       Date:  2014-02-07       Impact factor: 5.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.